BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts

BACKGROUND: Germline mutations of the BRCA tumour suppressors have been associated with increased risk of pancreatic cancer. Clinical evidence suggests that these patients may be more sensitive to treatment with cisplatin. As the frequency of germline BRCA mutations is low, definitive experimental d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Lohse, I, Borgida, A, Cao, P, Cheung, M, Pintilie, M, Bianco, T, Holter, S, Ibrahimov, E, Kumareswaran, R, Bristow, R G, Tsao, M-S, Gallinger, S, Hedley, D W
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2015
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4522629/
https://ncbi.nlm.nih.gov/pubmed/26180923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.220
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars